Vernakalant Hydrochloride
| Evidence Level: L5 | Predicted Indications: 50 |
Quick Overview
| Item | Value |
|---|---|
| Drug Name | Vernakalant Hydrochloride |
| DrugBank ID | DB06217 |
| Brand Names (EU) | Brinavess |
| Evidence Level | L5 |
| Predicted Indications | 50 |
| Top Prediction Score | 99.83% |
Approved Indication (EMA)
Rapid conversion of recent onset atrial fibrillation to sinus rhythm in adults: for non-surgery patients: atrial fibrillation </= 7 days duration; for post-cardiac surgery patients: atrial fibrillation </= 3 days duration.
Predicted New Indications
TxGNN model predictions for potential drug repurposing:
| Rank | Indication | Score | Source |
|---|---|---|---|
| 1 | stroke disorder | 99.83% | DL |
| 2 | atrial fibrillation (disease) | 99.61% | DL |
| 3 | sick sinus syndrome 2, autosomal dominant | 99.55% | DL |
| 4 | obsolete susceptibility to ischemic stroke | 99.43% | DL |
| 5 | sarcoglycanopathy | 99.32% | DL |
| 6 | Wildervanck syndrome | 99.29% | DL |
| 7 | ABri amyloidosis | 99.26% | DL |
| 8 | transient ischemic attack (disease) | 98.99% | DL |
| 9 | macrocephaly, dysmorphic facies, and psychomotor retardation | 98.91% | DL |
| 10 | obesity disorder | 98.81% | DL |
| 11 | hypervitaminosis | 98.76% | DL |
| 12 | cerebrovascular disorder | 98.75% | DL |
| 13 | spinal cord ischemia | 98.54% | DL |
| 14 | manic bipolar affective disorder | 98.48% | DL |
| 15 | proximal 16p11.2 microdeletion syndrome | 97.73% | DL |
| 16 | duodenal obstruction | 97.40% | DL |
| 17 | brain stem infarction | 97.08% | DL |
| 18 | obsolete hypertelorism (disease) | 96.93% | DL |
| 19 | cerebral artery occlusion | 95.99% | DL |
| 20 | frontorhiny | 95.88% | DL |
Showing top 20 of 50 predictions.
About TxGNN Predictions
Prediction Sources
| Source | Description |
|---|---|
| KG | Knowledge Graph - Network topology-based associations |
| DL | Deep Learning - Neural network score prediction |
Evidence Levels
| Level | Definition |
|---|---|
| L1 | Multiple Phase 3 RCTs / Systematic Reviews |
| L2 | Single RCT or multiple Phase 2 trials |
| L3 | Observational studies / Large case series |
| L4 | Preclinical / Mechanistic / Case reports |
| L5 | AI prediction only (current) |
Clinical Validation Needed
Research Use Only: These predictions are computational hypotheses that require clinical validation. They should NOT be used for clinical decision-making.
Next Steps for Validation
- Literature Review: Search PubMed for existing evidence
- Clinical Trial Search: Check ClinicalTrials.gov for ongoing studies
- Mechanistic Analysis: Evaluate biological plausibility
- Preclinical Studies: Conduct in vitro/in vivo validation
- Clinical Trials: Design and conduct human studies
Data Access
- FHIR API:
/fhir/ClinicalUseDefinition/ - CSV Download: All Predictions
- GitHub: yao-care/EuTxGNN
Citation
If using this data, please cite:
@article{huang2023txgnn,
title={A foundation model for clinician-centered drug repurposing},
author={Huang, Kexin and others},
journal={Nature Medicine},
year={2023},
doi={10.1038/s41591-023-02233-x}
}
Disclaimer: This report is for research purposes only and does not constitute medical advice. Drug repurposing predictions require rigorous clinical validation before any therapeutic application.